Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BENZYDAMINE HCL

All products: not a benefit

Tantum · DIN 01966065 · 0.15% · Oral Rinse

Listed, not a benefitDormant since 2021-03-09 · checked 2026-09-02 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 240
Reason for Use code 240 For the symptomatic relief of treatment induced mucositis in cancer patients. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Tantum · DIN 01966065 Manufacturer: Graceway Pharmaceuticals; listing date 1996-10-01 Health Canada: Dormant since 2021-03-09 · brand TANTUM · ATC A01AD02 BENZYDAMINE, A01AD02 BENZYDAMINE · form Mouthwash/gargle · route Buccal · ingredients BENZYDAMINE HYDROCHLORIDE 0.15 %/W/V · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Tantum: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13579 · Verify on the e-Formulary ↗ (DIN 01966065)

Source record
DIN 01966065: Tantum Raw flags: notABenefit=Y, sec3=Y Item: 521600002; group id 603; item number 1563; lccId 00081; manufacturer id GRA Source form: Oral Rinse; strength: 0.15% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01966065 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13579
Interchangeable products
Odan-Benzydamine · DIN 02463105 · not recorded PMS-Benzydamine · DIN 02239537 · not recorded Pharixia · DIN 02229777 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01966065
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-03-09 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:16 Local Anesthetics) and how they are covered
No products matched this class search: “52:16”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE PHARIXIA (benzydamine hydrochloride) is indicated for the relief of pain in acute sore throat and for the symptomatic relief of oro-pharyngeal mucositis caused by radiation therapy. https://pdf.hres.ca/dpd_pm/00022448.PDF PM date: not printed or not captured Source product: PHARIXIA; DIN 02229777; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Tantum: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026